Robert G Hoff, MD | |
200 Abbott Park Rd, Abbott Park, IL 60064-3503 | |
(847) 938-0609 | |
Not Available |
Full Name | Robert G Hoff |
---|---|
Gender | Male |
Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
Location | 200 Abbott Park Rd, Abbott Park, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699714691 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 59510 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Robert G Hoff, MD 200 Abbott Park Rd, Abbott Park, IL 60064-3503 Ph: (847) 938-0609 | Robert G Hoff, MD 200 Abbott Park Rd, Abbott Park, IL 60064-3503 Ph: (847) 938-0609 |
News Archive
U. S. Department of Health and Human Services Secretary Kathleen Sebelius recently announced the release of $15,000,000 for the operation of 10 nurse managed health clinics to support the education and training of nurse practitioners. Nurse managed health centers staffed by nurse practitioners provide comprehensive primary health care services to populations living in medically underserved communities.
Annie Henderson, 69, suffers from multiple chronic ailments, including kidney failure and mitral valve insufficiency. The later turned her life into a battle for breath, eliminating almost all activities and even making sleep a struggle. She couldn't sleep for more than 20-minutes at a time without waking in a fit of coughing. Thanks to a leading-edge procedure performed at UT Southwestern Medical Center, Mrs. Henderson is now breathing - and sleeping - easy.
The FDA announced Thursday that it is beginning a pilot project with Medicare officials in an effort to get new medical products covered sooner for the nation's 45 million senior citizens. Under the proposal, the FDA would review and make approval decisions alongside the Centers for Medicare and Medicaid Services, which decides whether and how to pay for new medical products for its elderly and disabled patients once they are approved for the U.S. market," Reuters reported.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
The Wall Street Journal on Monday examined how some hospitals are "adopting a policy to improve their finances: making medical care contingent on upfront payments."
› Verified 8 days ago